
Loading, please wait...

Loading, please wait...

Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of heart attacks in young women. Clinicians often observe a significant link between SCAD and oral contraceptives, particularly in patients without traditional risk factors. A recent case report highlights a 32-year-old woman who experienced an acute myocardial infarction (AMI) while taking combined hormonal birth control for four months.
While the exact mechanism remains unclear, hormonal factors significantly influence arterial wall integrity. Consequently, the high estrogen states associated with SCAD and oral contraceptives may predispose individuals to intimal tears or intramural hematomas. In this specific case, the patient presented with acute chest pain and ST-segment elevation. Coronary angiography initially showed diffuse narrowing of the left anterior descending (LAD) artery. However, the condition improved after intracoronary nitroglycerin administration. Subsequent optical coherence tomography (OCT) confirmed an intramural hematoma, which is a hallmark of SCAD.
Early identification is crucial for achieving favorable outcomes in young female patients presenting with acute coronary syndrome. Therefore, physicians must maintain a high clinical suspicion of SCAD when traditional atherosclerotic risks are absent. In this case, the medical team opted for conservative management rather than invasive stenting. Follow-up imaging at six weeks showed significant healing of the vessel. Furthermore, the patient recovered fully with normalized left ventricular function at the one-year mark. This outcome supports the current preference for non-invasive strategies in stable SCAD patients.
Exogenous hormones can alter the proteoglycan composition and collagen synthesis within the arterial media. These changes potentially weaken the vessel wall, making it susceptible to spontaneous dissection under stress.
While coronary angiography is the first step, advanced intravascular imaging like Optical Coherence Tomography (OCT) or Intravascular Ultrasound (IVUS) provides definitive evidence of intramural hematomas or false lumens.
Typically, clinicians recommend discontinuing systemic hormonal contraceptives after a SCAD event. Patients should instead consider non-hormonal alternatives or progestin-only intrauterine devices to minimize recurrence risks.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A case report detailing a 32-year-old woman's AMI caused by SCAD linked to oral contraceptive use, emphasizing diagnostic suspicion and conservative managem...
6 months ago

The Delhi government and DSACS have launched a two-month intensified HIV awareness initiative targeting youth, schools, and local communities. The drive strengthens decentralized testing, expands antiretroviral therapy linkages, ensures legal safeguards under the HIV Act 2017, and provides crucial financial aid.
Today

A multicenter MPOG database study of 289,047 cesarean delivery cases analyzed adherence to obstetric anesthesia best practices. General anesthesia avoidance reached 97.0%, while post-spinal vasopressor infusions (55.4%) and hypothermia prevention (56.7%) showed the lowest compliance, highlighting key targets.
Yesterday

A comprehensive meta-analysis shows digital health technologies significantly improve 6-minute walk distance and peak oxygen uptake in chronic heart failure patients, highlighting the clinical promise of structured remote cardiac rehabilitation.
Today

Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today

A comprehensive analysis of continuous glucose monitoring systems under European Medical Device Regulation 2017/745, examining conformity assessment challenges, Notified Body backlogs, EUDAMED rollout delays, and the critical need for transparent post-market surveillance.
Today